PRAME expression and clinical outcome of breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6604494.pdf
Reference18 articles.
1. Bernards R, Weinberg RA (2002) A progression puzzle. Nature 418: 823
2. Boon K, Edwards JB, Siu IM, Olschner D, Eberhart CG, Marra MA, Strausberg RL, Riggins GJ (2003) Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene 22: 7687–7694
3. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98: 1183–1192
4. Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O'Driscoll L (2008) Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat 109: 359–365
5. Epping MT, Bernards R (2006) A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 66: 10639–10642
Cited by 95 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Next-generation cancer vaccines and emerging immunotherapy combinations;Trends in Cancer;2024-08
2. PRAME expression in genital melanocytic lesions – Potential diagnostic pitfall of intermediate expression in atypical genital nevi;Pathology - Research and Practice;2024-08
3. Clinical implication of PRAME immunohistochemistry in differentiating melanoma in situ and dysplastic nevus in non‐acral nevus‐associated melanoma in situ: An institutional experience and meta‐analysis;Journal of Cutaneous Pathology;2024-06-21
4. The germline genetics of mild-to-moderate penetrance: An intriguing role of PRAME in multiple carcinogenesis;Genes & Diseases;2024-05
5. Tumor antigen PRAME is a potential therapeutic target of p53 activation in melanoma cells;BMB Reports;2024-04-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3